MAM
Toaster elevates Ira G & Bhawika Chhabra to CCO & MD, respectively
Mumbai: Toaster, the London-based digital-first full-service creative agency, has announced a significant elevation of its senior leadership in India with Ira G being promoted to chief creative officer (CCO) and Bhawika Chhabra to managing director (MD), effective immediately.
The India operations of Toaster has witnessed noticeable growth in the past 3 years on the back of delivering award-winning work for Google India and onboarding new clients such as Myntra, Bumble, OYO, Nykaa, and a few more to its roster. The agency has bagged awards like Kyoorius, MMA Smarties (APAC & India), Campaign India DigiCrest Awards, ET Brand Equity DG+, e4m IMA Awards and many more for its campaign work for Google India.
Ira has written dialogues for Netflix’s Class and Feels Like Ishq and has featured as a jury for YouTube Works Awards & Campaign India Film Crest Awards this year. Chhabra, who helped set up Toaster in India eight years ago, has donned multiple hats from managing new businesses agenda to spearheading large scale campaigns, and growing the company into its new avatar today.
Toaster co-founder & CEO Tom Dunn said, “Bhawika & Ira have built a formidable partnership and have played instrumental roles in shaping the agency in India, setting a standard as a high performing, multi-award winning team. We’re proud to announce this double promotion and look forward to exciting times for Toaster in the region – building on the highest standards of creativity, continuing to deliver innovative and meaningful work to our clients, and fostering a workplace that people thrive in.”
Commenting on the announcement, Ira said, “I’m elated with this news. Our endeavour has been to foster an idea-first creative culture within Toaster and I feel that over the last 3 years we’ve successfully transitioned from handling pure digital mandates to now managing full-scale integrated creative campaigns. For the next phase of our growth, we’re keen to induct new & diverse talent and continue to build on the culture we’ve developed that we’re quite proud of.”
Chhabra added, “I’m quite proud of how far we’ve come. We’ve got a great momentum going and our plan is to further strengthen client partnerships, acquire new businesses, and deliver higher profitability – all this while delivering the best creative work for our clients. A shout out to our client partners at Google India for their trust in us – who are an important chapter of our growth story.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
